Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03868423
Recruitment Status : Recruiting
First Posted : March 11, 2019
Last Update Posted : January 18, 2020
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Sameek Roychowdhury, Ohio State University Comprehensive Cancer Center

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 30, 2020
Estimated Study Completion Date : December 30, 2020